Longevity education

Stay curious about aging well — without pretending to be your clinician.

Read today's research headlines, run honest calculators, keep a private record, and assemble an educational supplement protocol. Not a clinic.

Latest news Open calculators Build your protocol

Health sync

Get the app. Sync HealthKit or Health Connect.

Tracker is the hub: install the VitaLonga iOS/Android app, grant Health, then scan the signed-in QR to log the phone into your member. File import stays as a fallback. Educational numbers only — not medical advice.

Open Tracker Create a member record

Today's news

Newest story: 27 Oct 2026

News archive →

EurekAlert · 26 Oct 2026 · Supplements / medicine

A phase 3 trial tested a cancer drug after endometrial cancer treatment

NYU Langone reported on 26 October 2026 a phase 3 trial of sacituzumab tirumotecan, a cancer drug, in women already treated for endometrial cancer. 386 women assigned the drug had a 41 percent lower risk of the cancer growing or spreading than 390 women given chemotherapy, the release says. Frequent side effects included low blood counts, mouth soreness, and dry eyes, which the investigators called manageable. Initial data were presented at ESMO and posted in The Lancet. The release does not give an age band. This is a trial of a prescribed cancer medicine, not a supplement someone should start from a headline. Not medical advice.

Read at EurekAlert →♡ Save

study

EurekAlert · 26 Oct 2026 · Research

A lab study found fibrils can carry RNA into sperm

Columbia's Zuckerman Institute reported in Molecular Cell on 26 October 2026 that amyloid fibrils ferried RNA into sperm, including strands long enough to encode a fluorescent marker. Embryos from that sperm made at least ten times more of the marker than sperm given the RNA alone. The release frames this as a laboratory delivery finding. It is not a fertility treatment. Not medical advice.

Read at EurekAlert →♡ Save

study

EurekAlert · 26 Oct 2026 · Aging

An extra year of school lined up with fewer dementia diagnoses decades later

On 26 October 2026, University of Southern California researchers described a study of the 1972 British reform that raised the school-leaving age from 15 to 16. The share staying until at least 16 rose by 14 percentage points. In UK Biobank records followed through age 65, people born just after the cutoff were less likely to have a dementia diagnosis, including among those with high genetic risk. This is a schooling comparison in existing health records. Not medical advice.

Read at EurekAlert →♡ Save